Literature DB >> 22449664

Cardiac safety of donepezil in elderly patients with Alzheimer disease.

Ahmet Turan Isik1, Gulsen Babacan Yildiz, Ergun Bozoglu, Adnan Yay, Emine Aydemir.   

Abstract

OBJECTIVE: Donepezil is a widely used cholinesterase inhibitor for the treatment of Alzheimer's disease (AD), however its cholinergic adverse side effects on the cardiovascular system are still unclear. In this study, we aimed to examine the adverse side effects caused by donepezil on cardiac rhythm and postural blood pressure changes in elderly patients with Alzheimer Disease.
METHODS: The ECG parameters including heart rate, PR, QT, QTc interval and QRS duration and postural blood pressure changes were recorded at the baseline and at each donepezil dose level (5 and 10 mg/d). Patients Seventy-one consecutive patients who were referred by primary care centers to a Geriatric Clinic were enrolled and underwent comprehensive geriatric assessment.
RESULTS: Fifty-two subjects completed the study. There were no significant changes relative to the baseline in any of the ECG parameters or arterial blood pressure at any of the investigated dosages of donepezil.
CONCLUSION: It was demonstrated that donepezil was not associated with increased negative chronotropic, arrhythmogenic or hypotensive effects for elderly patients with Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449664     DOI: 10.2169/internalmedicine.51.6671

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil.

Authors:  Kenneth Grasing; Deepan Mathur; Cherilyn DeSouza; Thomas F Newton; David E Moody; Marc Sturgill
Journal:  Am J Addict       Date:  2016-07-08

2.  QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine.

Authors:  Katie Malone; Jules C Hancox
Journal:  Ther Adv Drug Saf       Date:  2020-08-17

3.  Management of Psychiatric Disorders in Patients with Cardiovascular Diseases.

Authors:  Prasad Rao Gundugurti; Ranjan Bhattacharyya; Amulya Koneru
Journal:  Indian J Psychiatry       Date:  2022-03-23       Impact factor: 2.983

Review 4.  Cardiovascular effects of drugs used to treat Alzheimer's disease.

Authors:  Laurence Guy Howes
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

5.  Nicotinic receptors in neurodegeneration.

Authors:  Inmaculada Posadas; Beatriz López-Hernández; Valentín Ceña
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

6.  Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease.

Authors:  Deguo Wang; Yong Wu; Ancai Wang; Yueyun Chen; Ting Zhang; Nengwei Hu
Journal:  Cardiol Res Pract       Date:  2018-04-23       Impact factor: 1.866

Review 7.  QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.

Authors:  Yasar Torres-Yaghi; Amelia Carwin; Jacob Carolan; Steven Nakano; Fahd Amjad; Fernando Pagan
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-24       Impact factor: 2.570

8.  PLGA Microspheres with Alginate-Coated Large Pores for the Formulation of an Injectable Depot of Donepezil Hydrochloride.

Authors:  Dohyun Kim; Tae Hee Han; Seong-Chul Hong; Sun Jae Park; Yong Hak Lee; Hyeongmin Kim; Minwoo Park; Jaehwi Lee
Journal:  Pharmaceutics       Date:  2020-04-01       Impact factor: 6.321

9.  Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report.

Authors:  Hong-Chun Li; Ke-Xue Luo; Jie-Sheng Wang; Qin-Xian Wang
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.